Genesys [GENESYS] vs Nucleus Software [NUCLEUS] Detailed Stock Comparison
Genesys
NSE
Loading...
Nucleus Software
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Genesys wins in 6 metrics, Nucleus Software wins in 13 metrics, with 0 ties. Nucleus Software appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Genesys | Nucleus Software | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 41.33 | 16.48 | Nucleus Software |
| Price-to-Book Ratio | 4.26 | 3.38 | Nucleus Software |
| Debt-to-Equity Ratio | 21.93 | 0.25 | Nucleus Software |
| PEG Ratio | 1.35 | 0.89 | Nucleus Software |
| EV/EBITDA | 16.64 | 14.08 | Nucleus Software |
| Profit Margin (TTM) | 17.77% | 19.66% | Nucleus Software |
| Operating Margin (TTM) | 19.85% | 14.05% | Genesys |
| EBITDA Margin (TTM) | 19.85% | 14.05% | Genesys |
| Return on Equity | 10.09% | 20.02% | Nucleus Software |
| Return on Assets (TTM) | 7.23% | 14.14% | Nucleus Software |
| Free Cash Flow (TTM) | $-1.07B | $1.36B | Nucleus Software |
| Dividend Yield | N/A | 1.08% | N/A |
| 1-Year Return | -16.99% | -24.16% | Genesys |
| Price-to-Sales Ratio (TTM) | 7.63 | 3.22 | Nucleus Software |
| Enterprise Value | $25.32B | $23.96B | Genesys |
| EV/Revenue Ratio | 7.76 | 2.80 | Nucleus Software |
| Gross Profit Margin (TTM) | 51.03% | 33.15% | Genesys |
| Revenue per Share (TTM) | $82 | $323 | Nucleus Software |
| Earnings per Share (Diluted) | $14.43 | $63.47 | Nucleus Software |
| Beta (Stock Volatility) | -0.57 | -0.24 | Genesys |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Genesys vs Nucleus Software Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Genesys | -0.39% | 4.17% | -2.64% | -19.27% | -17.81% | -39.13% |
| Nucleus Software | 0.02% | 4.59% | -4.23% | -18.70% | 23.87% | 0.75% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Genesys | -16.99% | 2.56% | 997.33% | 1,006.49% | 160.27% | 4,740.91% |
| Nucleus Software | -24.16% | 156.12% | 95.42% | 311.90% | 711.17% | 629.00% |
Performance & Financial Health Analysis: Genesys vs Nucleus Software
| Metric | GENESYS | NUCLEUS |
|---|---|---|
| Market Information | ||
| Market Cap | ₹24.89B | ₹27.53B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 117,477 | 17,368 |
| 90 Day Avg. Volume | 145,855 | 50,550 |
| Last Close | ₹594.10 | ₹1,045.80 |
| 52 Week Range | ₹524.00 - ₹1,055.00 | ₹725.00 - ₹1,420.00 |
| % from 52W High | -43.69% | -26.35% |
| All-Time High | ₹1,055.00 (Jan 20, 2025) | ₹1,787.50 (Jan 22, 2024) |
| % from All-Time High | -43.69% | -41.49% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.27% | 0.11% |
| Quarterly Earnings Growth | 0.32% | 0.17% |
| Financial Health | ||
| Profit Margin (TTM) | 0.18% | 0.20% |
| Operating Margin (TTM) | 0.20% | 0.14% |
| Return on Equity (TTM) | 0.10% | 0.20% |
| Debt to Equity (MRQ) | 21.93 | 0.25 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹139.86 | ₹309.29 |
| Cash per Share (MRQ) | ₹4.40 | ₹136.33 |
| Operating Cash Flow (TTM) | ₹-1,066,629,000 | ₹2.28B |
| Levered Free Cash Flow (TTM) | ₹562.23M | ₹1.63B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.08% |
| Last 12-Month Dividend | ₹0.00 | ₹12.50 |
Valuation & Enterprise Metrics Analysis: Genesys vs Nucleus Software
| Metric | GENESYS | NUCLEUS |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 41.33 | 16.48 |
| Forward P/E | 43.85 | 37.15 |
| PEG Ratio | 1.35 | 0.89 |
| Price to Sales (TTM) | 7.63 | 3.22 |
| Price to Book (MRQ) | 4.26 | 3.38 |
| Market Capitalization | ||
| Market Capitalization | ₹24.89B | ₹27.53B |
| Enterprise Value | ₹25.32B | ₹23.96B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 7.76 | 2.80 |
| Enterprise to EBITDA | 16.64 | 14.08 |
| Risk & Other Metrics | ||
| Beta | -0.57 | -0.24 |
| Book Value per Share (MRQ) | ₹139.86 | ₹309.29 |
Financial Statements Comparison: Genesys vs Nucleus Software
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | GENESYS | NUCLEUS |
|---|---|---|
| Revenue/Sales | ₹941.64M | ₹2.18B |
| Cost of Goods Sold | ₹370.71M | ₹1.46B |
| Gross Profit | ₹570.93M | ₹721.70M |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹344.92M | ₹305.80M |
| EBITDA | ₹498.84M | ₹519.40M |
| Pre-Tax Income | ₹315.17M | ₹483.00M |
| Income Tax | ₹125.20M | ₹131.00M |
| Net Income (Profit) | ₹189.97M | ₹352.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | GENESYS | NUCLEUS |
|---|---|---|
| Cash & Equivalents | ₹33.44M | ₹501.60M |
| Total Current Assets | ₹4.55B | ₹5.44B |
| Total Current Liabilities | ₹1.89B | ₹2.83B |
| Long-Term Debt | ₹222.61M | ₹8.80M |
| Total Shareholders Equity | ₹5.57B | ₹8.14B |
| Retained Earnings | N/A | ₹7.67B |
| Property, Plant & Equipment | ₹667.55M | ₹470.30M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | GENESYS | NUCLEUS |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | GENESYS | NUCLEUS |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 117,477 | 17,368 |
| Average Daily Volume (90 Day) | 145,855 | 50,550 |
| Shares Outstanding | 39.80M | 26.33M |
| Float Shares | 18.60M | 6.61M |
| % Held by Insiders | 0.47% | 0.76% |
| % Held by Institutions | 0.05% | 0.03% |
Dividend Analysis & Yield Comparison: Genesys vs Nucleus Software
| Metric | GENESYS | NUCLEUS |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | ₹12.50 |
| Last 12-Month Dividend Yield | N/A | 1.08% |
| 3-Year Avg Annual Dividend | ₹0.00 | ₹11.67 |
| 3-Year Avg Dividend Yield | N/A | 0.93% |
| 3-Year Total Dividends | ₹0.00 | ₹35.00 |
| Ex-Dividend Date | N/A | Jul 11, 2025 |